Fazel Shokri

Prof. Fazel Shokri


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
VKVahid Molla Kazemiha
Vahid Molla Kazemiha
MSMohammad ali Shokrgozar
Mohammad ali Shokrgozar
MAMohammad Arabestani
Mohammad Arabestani
MMMorteza Shojaei Moghadam
Morteza Shojaei Moghadam
SAShahram Azari
Shahram Azari
FSFazel Shokri
Fazel Shokri

27 December 2012 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
GGGhasem Ghalamfarsa
Ghasem Ghalamfarsa
AMAli Memarian
Ali Memarian
HAHossein Asgarian-Omran
Hossein Asgarian-Omran
SRSeyed Mohsen Razavi
Seyed Mohsen Razavi
FSFazel Shokri
Fazel Shokri

5 January 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
FAFatemeh Atyabi
Fatemeh Atyabi
ARAli Rastegari
Ali Rastegari
EMEsmail Mollarazi
Esmail Mollarazi
MKMelika Kiani
Melika Kiani
FSFazel Shokri
Fazel Shokri

6 June 2012 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
BABita Ansaripour
Bita Ansaripour
SRSeyed Mohsen Razavi
Seyed Mohsen Razavi
RSRamazan Ali Sharifian
Ramazan Ali Sharifian
FSFazel Shokri
Fazel Shokri

3 January 2013 in Cancer Investigation
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
MYMehdi Yousefi
Mehdi Yousefi
AMAli Memarian
Ali Memarian
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
JKJalal Khoshnoodi
Jalal Khoshnoodi
FSFazel Shokri
Fazel Shokri
Little is known regarding the immunobiology of regulatory T (Treg) cells in hematopoietic malignancies, particularly in chronic lymphocytic leukemia (CLL). In the present study, we showed that the frequencies of CD8+ and CD4+ Treg cells were significantly increased in progressive as compared with indolent CLL patients and normal subjects. Enriched CD4+ Treg cells induced a similar level of inhibition in polyclonally activated B cells and effector T cells from CLL patients and normal subjects. Our results suggest that the increase in circulating Treg cells may result in downregulation of tumor-specific immune response, leading to tumor expansion and disease progression.

17 May 2013 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FJFarhad Jadidi-Niaragh
Farhad Jadidi-Niaragh
GGGhasem Ghalamfarsa
Ghasem Ghalamfarsa
MYMehdi Yousefi
Mehdi Yousefi
MTMina Hajifaraj Tabrizi
Mina Hajifaraj Tabrizi
FSFazel Shokri
Fazel Shokri